Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 2, 2007, Pages 436-439

  Moltó, José ^a,b   Santos, José Ramón ^a   Negredo, Eugenia ^a   Miranda, Cristina ^a   Videla, Sebastià ^a   Clotet, Bonaventura ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

HIV infection; Nucleoside sparing therapy; Protease inhibitors

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMPAIRED GLUCOSE TOLERANCE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DATABASES, FACTUAL; ENDPOINT DETERMINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 34547837584     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm198     Document Type: Article

References (12)

1. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.
2. Brinkman K, Hofstede H, Burger DMI et al. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
3. Arribas JR, Pulido F, Delgado R et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of randomized, controlled, open label, proof of concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40 280-7.
4. Kahlert C, Hupfer M, Wagels T et al. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18: 955-7.
5. Swindells S, DI Rienzo A, Wilkin T et al. Regimen simplification of atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296: 806-14.
6. Arribas J, Pulido F, Delgado R et al. Lopinavir/ritonavir as single-drug maintenance therapy in patents with HIV-1 viral suppression: forty eight week results of a randomized, controlled, open label, clinical trial (OK04 Study). In: Abstracts of the Fifteenth International AIDS Conference, Toronto, 2006. Abstract THLB0203. http://www.iasociety.org/ejias-search/show.asp?abstract_id= 2201333&iConferenceID=2006 (3 May 2007, date last accessed).
7. Havlir DV, Marschner IC, Hirsch MS et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple drug therapy. N Engl J Med 1998; 339: 1261-8.
8. Kempf DJ, Isaacson JD, King MS et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Infect Dis 2001; 75: 7462-9.
9. Kempf DJ, King MS, Berntein B et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189: 51-60.
10. Murphy RL, Brun S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15: F1-9.
11. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002; 15: 247-77.
12. Llibre JM, Pere D, Palacios R et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006; 20: 1407-14.